跳转至内容
Merck
CN
  • Identification of highly concentrated dextrose solution (50% dextrose) extravasation and treatment--a clinical report.

Identification of highly concentrated dextrose solution (50% dextrose) extravasation and treatment--a clinical report.

The American journal of emergency medicine (2013-04-23)
Sarah L Lawson, William Brady, Ahmed Mahmoud
摘要

Treatment for significant hypoglycemia includes administration of dextrose containing agents, including 50% dextrose (D50%W) intravenously. Significant extravasation of D50%W can lead to complications, including skin and soft tissue injury, loss of limb, or death. The aim of this case report, using an interdisciplinary team approach, explores extravasation protocols as well as literature review, is to provide information about the proper use of hyaluronidase in patients with D50%W extravasations. A 46-year-old African American man presented to the emergency department (ED) after blood glucose level was initially 13 mg/dL. Emergency medical service established a large bore intravenous (IV) line in the right antecubital vein and administered a total of 50 g of D50%W. Upon arrival to the ED, the patient's level of consciousness had significantly improved. After arrival to the ED, the patient started complaining of pain in his right arm, near the site of the IV line insertion. On inspection, the IV site was grossly infiltrated. Hospital protocols for hyperosmolar infiltration were used. Extravasation is a common medical complication of infused medications and needs to be properly identified and treated. The multitude of skills from nursing, medicine, and pharmacy ensures that extravasation is managed appropriately and effectively to ensure safety to patients. Recognition, communication, and awareness of the institutional guidelines on how to treat infiltration and extravasation should be encouraged in all ED and intensive care unit medical personnel who deal with a variety of infusions and IV medications that have serious implications if not treated correctly.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
D -(+)-葡萄糖, ≥99.5% (GC)
Sigma-Aldrich
透明质酸酶 来源于牛睾丸, Type I-S, lyophilized powder, 400-1000 units/mg solid
Sigma-Aldrich
D -(+)-葡萄糖, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99.5%
Sigma-Aldrich
D -(+)-葡萄糖 溶液, 45% in H2O, sterile-filtered, BioXtra, suitable for cell culture
Sigma-Aldrich
葡萄糖, 97.5-102.0% anhydrous basis, meets EP, BP, JP, USP testing specifications
Sigma-Aldrich
D -(+)-葡萄糖 溶液, 100 g/L in H2O, sterile-filtered, BioXtra, suitable for cell culture
Sigma-Aldrich
透明质酸酶 来源于牛睾丸, Type IV-S, lyophilized powder (essentially salt-free), 750-3000 units/mg solid
Sigma-Aldrich
D -(+)-葡萄糖, ≥99.5% (GC), BioXtra
Supelco
葡萄糖, Pharmaceutical Secondary Standard; Certified Reference Material
USP
右旋糖, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
D -(+)-葡萄糖, BioUltra, anhydrous, ≥99.5% (sum of enantiomers, HPLC)
Sigma-Aldrich
透明质酸酶 来源于牛睾丸, Type IV-S, powder, suitable for mouse embryo cell culture, 750-3000 units/mg solid
Sigma-Aldrich
D -(+)-葡萄糖, ACS reagent
Supelco
D -(+)-葡萄糖, analytical standard
Sigma-Aldrich
透明质酸酶 来源于绵羊睾丸, Type V, lyophilized powder, ≥1,500 units/mg solid
Sigma-Aldrich
透明质酸酶 来源于牛睾丸, Type VIII, lyophilized powder, 300-1,000 U/mg
Sigma-Aldrich
透明质酸酶 来源于绵羊睾丸, Type II, lyophilized powder, ≥300 units/mg solid
Sigma-Aldrich
D -(+)-葡萄糖, suitable for mouse embryo cell culture, ≥99.5% (GC)
Sigma-Aldrich
透明质酸酶 来源于牛睾丸, Type VI-S, lyophilized powder, 3,000-15,000 units/mg solid
Sigma-Aldrich
D -(+)-葡萄糖, Hybri-Max, powder, BioReagent, suitable for hybridoma
Sigma-Aldrich
D -(+)-葡萄糖, tested according to Ph. Eur.
Sigma-Aldrich
D-葡萄糖-12C6, 16O6, 99.9 atom % 16O, 99.9 atom % 12C
Supelco
D -(+)-葡萄糖 溶液, 1 mg/mL in 0.1% benzoic acid, standard for enzymatic assay kits GAGO20, GAHK20, STA20, analytical standard
Sigma-Aldrich
D -(+)-葡萄糖, Vetec, reagent grade, ≥99.5% (HPLC)